PURPOSE: This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administering O(6)-BG in combination with temozolomide. PATIENTS AND METHODS: Patients were accrued into two independent strata on the basis of histology: glioblastoma multiforme (GBM) and anaplastic glioma. Both temozolomide and O(6)-BG were administered on day 1 of a 28-day treatment cycle. Patients were administered a 1-hour O(6)-BG infusion at a dose of 120 mg/m(2) followed immediately by a 48-hour infusion at a dose of 30 mg/m(2)/d. Temozolomide was administered orally within 60 minutes of the end of the 1-hour O(6)-BG infusion at a dose of 472 mg/m(2). The primary end point was objective response rate. Secondary end points included progression-free survival, overall survival, and safety. RESULTS: Sixty-six of 67 patients who enrolled were treated with temozolomide and O(6)-BG. One of 34 patients (3%) with GBM (95% CI, 0.1% to 15%) and five of 32 assessable patients (16%) with anaplastic glioma (95% CI, 5% to 33%) were responders. The most commonly reported adverse events were grade 4 hematologic events experienced in 48% of the patients. CONCLUSION: O(6)-BG when added to a 1-day dosing regimen of temozolomide was able to restore temozolomide sensitivity in patients with temozolomide-resistant anaplastic glioma, but there seemed to be no significant restoration of temozolomide sensitivity in patients with temozolomide-resistant GBM.
PURPOSE: This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administering O(6)-BG in combination with temozolomide. PATIENTS AND METHODS: Patients were accrued into two independent strata on the basis of histology: glioblastoma multiforme (GBM) and anaplastic glioma. Both temozolomide and O(6)-BG were administered on day 1 of a 28-day treatment cycle. Patients were administered a 1-hour O(6)-BG infusion at a dose of 120 mg/m(2) followed immediately by a 48-hour infusion at a dose of 30 mg/m(2)/d. Temozolomide was administered orally within 60 minutes of the end of the 1-hour O(6)-BG infusion at a dose of 472 mg/m(2). The primary end point was objective response rate. Secondary end points included progression-free survival, overall survival, and safety. RESULTS: Sixty-six of 67 patients who enrolled were treated with temozolomide and O(6)-BG. One of 34 patients (3%) with GBM (95% CI, 0.1% to 15%) and five of 32 assessable patients (16%) with anaplastic glioma (95% CI, 5% to 33%) were responders. The most commonly reported adverse events were grade 4 hematologic events experienced in 48% of the patients. CONCLUSION:O(6)-BG when added to a 1-day dosing regimen of temozolomide was able to restore temozolomide sensitivity in patients with temozolomide-resistant anaplastic glioma, but there seemed to be no significant restoration of temozolomide sensitivity in patients with temozolomide-resistant GBM.
Authors: Jennifer A Quinn; James Pluda; M Eileen Dolan; Shannon Delaney; Richard Kaplan; Jeremy N Rich; Allan H Friedman; David A Reardon; John H Sampson; O Michael Colvin; Michael M Haglund; Anthony E Pegg; Robert C Moschel; Roger E McLendon; James M Provenzale; Sridharan Gururangan; Sandra Tourt-Uhlig; James E Herndon; Darell D Bigner; Henry S Friedman Journal: J Clin Oncol Date: 2002-05-01 Impact factor: 44.544
Authors: H S Friedman; J Pluda; J A Quinn; R B Ewesuedo; L Long; A H Friedman; I Cokgor; O M Colvin; M M Haglund; D M Ashley; J N Rich; J Sampson; A E Pegg; R C Moschel; R E McLendon; J M Provenzale; E S Stewart; S Tourt-Uhlig; A M Garcia-Turner; J E Herndon; D D Bigner; M E Dolan Journal: J Clin Oncol Date: 2000-10-15 Impact factor: 44.544
Authors: Monika E Hegi; Annie-Claire Diserens; Sophie Godard; Pierre-Yves Dietrich; Luca Regli; Sandrine Ostermann; Philippe Otten; Guy Van Melle; Nicolas de Tribolet; Roger Stupp Journal: Clin Cancer Res Date: 2004-03-15 Impact factor: 12.531
Authors: T Hotta; Y Saito; H Fujita; T Mikami; K Kurisu; K Kiya; T Uozumi; G Isowa; K Ishizaki; M Ikenaga Journal: J Neurooncol Date: 1994 Impact factor: 4.130
Authors: Plamen P Christov; Kinrin Yamanaka; Jeong-Yun Choi; Kei-ichi Takata; Richard D Wood; F Peter Guengerich; R Stephen Lloyd; Carmelo J Rizzo Journal: Chem Res Toxicol Date: 2012-07-06 Impact factor: 3.739
Authors: Troy H Dillard; S Humayun Gultekin; Johnny B Delashaw; Chris G Yedinak; Edward A Neuwelt; Maria Fleseriu Journal: Pituitary Date: 2011-03 Impact factor: 4.107
Authors: Jennifer E Adair; Brian C Beard; Grant D Trobridge; Tobias Neff; Jason K Rockhill; Daniel L Silbergeld; Maciej M Mrugala; Hans-Peter Kiem Journal: Sci Transl Med Date: 2012-05-09 Impact factor: 17.956
Authors: Ganesan Vaidyanathan; Benjamin White; Donna J Affleck; Darryl McDougald; Michael R Zalutsky Journal: Nucl Med Biol Date: 2010-10-27 Impact factor: 2.408
Authors: Jinkyu Jung; Leo Jy Kim; Xiuxing Wang; Qiulian Wu; Tanwarat Sanvoranart; Christopher G Hubert; Briana C Prager; Lisa C Wallace; Xun Jin; Stephen C Mack; Jeremy N Rich Journal: JCI Insight Date: 2017-05-18
Authors: David Svilar; Madhu Dyavaiah; Ashley R Brown; Jiang-bo Tang; Jianfeng Li; Peter R McDonald; Tong Ying Shun; Andrea Braganza; Xiao-hong Wang; Salony Maniar; Claudette M St Croix; John S Lazo; Ian F Pollack; Thomas J Begley; Robert W Sobol Journal: Mol Cancer Res Date: 2012-10-04 Impact factor: 5.852
Authors: A Gutenberg; C B Lumenta; W E K Braunsdorf; M Sabel; H M Mehdorn; M Westphal; A Giese Journal: J Neurooncol Date: 2013-03-28 Impact factor: 4.130
Authors: April C L Bostian; Leena Maddukuri; Megan R Reed; Tatsiana Savenka; Jessica H Hartman; Lauren Davis; Dakota L Pouncey; Grover P Miller; Robert L Eoff Journal: Chem Res Toxicol Date: 2015-12-30 Impact factor: 3.739